Evidence map›Paper›PMID 30345862›Full record

ArticleJournal of feline medicine and surgery2019

Profibrotic effects of angiotensin II and transforming growth factor beta on feline kidney epithelial cells.

Cyrina D van Beusekom, Tanja M Zimmering

Open access · bronzeAbstract read
In one paragraph

Article in Journal of feline medicine and surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Hormonal Regulation of Renal Fibrosis.Life (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Cyrina D van Beusekom1 Veterinary Pharmacology, Pharmacotherapy and Toxicology, Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-3726-9997
Tanja M Zimmering2 Boehringer Ingelheim Animal Health GmbH, Ingelheim, Germany.
Boehringer Ingelheim (Germany) · DEUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to evaluate the role of angiotensin II (AT-II) and its main mediator, transforming growth factor beta 1 (TGF-β1), in the development of feline renal fibrosis.

methodsExpression of marker genes indicating epithelial-to-mesenchymal transition (EMT), profibrotic mediators and matricellular proteins was measured in feline kidney epithelial cells (Crandell Rees feline kidney [CRFK] cells) after incubation with AT-II and/or TGF-β1.

resultsCells incubated with TGF-β1 or the combination of TGF-β1 with AT-II showed clear EMT with more stretched fibroblastic cells, whereas the cells incubated without TGF-β1 and AT-II (control) showed more epithelial cells. Gene expression of collagen type I ( CONCLUSIONS AND RELEVANCE: TGF-β1 significantly induced expression of the EMT marker gene α-SMA, profibrotic mediator

Indexed as

Epithelial CellsKidneyAngiotensin IIAnimalsCat DiseasesCatsCell LineEpithelial-Mesenchymal TransitionKidney DiseasesTransforming Growth Factor betaAngiotensin IITransforming Growth Factor betaAngiotensin IIchronic kidney diseasefibrosisrenal failureTGF-β

Identifiers

PMID30345862
PMCPMC6661713
OpenAlexW2897636161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.